DAPT using cilostazol, a therapeutic option for prevention of recurrent stroke without bleeding risk: Study
Japan: Dual antiplatelet therapy (DAPT) is the combination of aspirin and one ADP-receptor blocker. To reduce the risk of acute stent thrombosis the period of DAPT is preferable with prasugrel or ticagrelor. The long-term benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) for the prevention of recurrent stroke isn't known in patients with intracranial arterial stenosis.
A randomized trial by Shinichiro Uchiyama and team revealed that DAPT using cilostazol is superior to SAPT with clopidogrel or aspirin for the prevention of recurrent stroke and vascular events without increasing bleeding risk among patients with intracranial arterial stenosis after stroke. The findings of the study are published in the Journal of the American Heart Association (JAHA).
The objective of the study was to compare the efficacy and safety of DAPT with cilostazol and clopidogrel or aspirin to those of SAPT with clopidogrel or aspirin in patients with intracranial arterial stenosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.